9 Result(s)

Article

An unusual, activating insertion/deletion MPL mutant in primary myelofibrosis

J-P Defour, Y Hoade, A-M Reuther, A Callaway, D Ward, F Chen… in Leukemia (2017)

Article

Rethinking JAK2 inhibition: towards novel strategies of more specific and versatile janus kinase inhibition

Janus kinases (JAKs) are required for cytokine receptor signaling. Since the discovery of the highly prevalent JAK2 V617F mutation in myeloproliferative neoplasms (MPNs), JAK2 became a prime target for inhibit...

E Leroy, S N Constantinescu in Leukemia (2017)

Article

Pathologic activation of thrombopoietin receptor and JAK2-STAT5 pathway by frameshift mutants of mouse calreticulin

T Balligand, Y Achouri, C Pecquet, I Chachoua, H Nivarthi, C Marty… in Leukemia (2016)

Article

Oncogenic activation of MPL/thrombopoietin receptor by 17 mutations at W515: implications for myeloproliferative neoplasms

J-P Defour, I Chachoua, C Pecquet, S N Constantinescu in Leukemia (2016)

Article

Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution

X Cabagnols, J P Defour, V Ugo, J C Ianotto, P Mossuz, J Mondet, F Girodon… in Leukemia (2015)

Article

Aberrant signal transduction pathways in myeloproliferative neoplasms

The BCR-ABL-negative myeloproliferative neoplasms (MPNs), polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF), entered the spotlight in 2005 when the unique somatic acquired JAK...

J Kota, N Caceres, S N Constantinescu in Leukemia (2008)